INCY logo

Incyte

INCY · What the business does, what can go wrong, and how options sellers approach it

What it does

Incyte is a biopharmaceutical company that discovers and develops medicines, mostly small-molecule drugs. Its work centers on oncology (including blood cancers) and dermatology. It also runs a research pipeline aimed at replacing or extending its current products.

How it makes money

Most revenue comes from selling approved drugs, led by Jakafi, which treats certain rare blood cancers and graft versus host disease. Opzelura, a topical cream for skin conditions such as atopic dermatitis and vitiligo, is a newer product line.

Incyte also earns royalties and milestone payments from partners. Novartis sells ruxolitinib (as Jakavi) outside the U.S. and markets Tabrecta, and Lilly sells Olumiant for rheumatoid arthritis. Incyte's other oncology products add smaller amounts.

Why investors own it

  • Jakafi is an established, profitable product in a niche with high unmet need, which funds research internally.
  • Partnership royalties add revenue that needs little extra spending.
  • Opzelura and the pipeline offer a path to diversify beyond one drug.
  • Biotech companies with approved products and cash flow sometimes attract investors who want drug-development exposure with less pure-pipeline risk.

What can go wrong

  • Concentration: One drug has historically driven a large share of sales, so problems with it matter a lot.
  • Patent expiry: Key protection for Jakafi eventually ends, and generic competition could follow.
  • Clinical and regulatory risk: Trials can fail and approvals can be delayed or denied.
  • Pricing pressure: Drug pricing policy and insurer negotiations can reduce revenue.
  • Safety labeling: The JAK inhibitor class carries safety warnings that can limit use.

What to watch

  • Jakafi prescription trends and net sales
  • Opzelura growth and new indications
  • Pipeline trial readouts and regulatory decisions
  • Progress on products meant to succeed Jakafi
  • Royalty income from partners
  • Patent and litigation developments
  • Operating spending on research and development

Options income angle

Options on INCY are generally available across several expirations and are usually reasonably liquid, though trading is thinner than in the largest pharma names. Check bid-ask spreads before trading, especially in far strikes.

Implied volatility tends to rise ahead of earnings, clinical trial data, FDA decisions and conference presentations, then often falls once the news is out.

One caution for premium sellers: biotech stocks can gap sharply on trial or regulatory news. A short call can be exercised after a sudden rally, and a short put can lose heavily after a sharp drop. The premium collected may not cover a large move, so event dates are worth knowing before selling options.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 10, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Incyte reported net income of $1,286.7 million for 2025, compared with $32.6 million in 2024. Revenue grew across most products, and a settlement with Novartis lowered the company's royalty costs. The filing is also clear that JAKAFI, its main product, loses patent exclusivity in 2028, and generic makers are already challenging its patents in court.

How the business did

  • Total revenues were $5,141.2 million, against $4,241.2 million in 2024. JAKAFI net revenues were $3,092.5 million, which management attributes mainly to higher paid demand across all indications.
  • OPZELURA net revenues were $678.5 million, up from $508.3 million, including $130.0 million from outside the U.S. (mainly France and Italy, for vitiligo). NIKTIMVO, launched in the first quarter of 2025, brought in $151.6 million. ZYNYZ rose to $66.3 million from $3.2 million after its approval in squamous cell anal carcinoma.
  • Two items distort the year-over-year comparison. In 2024, research expense included $679.4 million for in-process research and development (unfinished drug assets bought and expensed) from the Escient acquisition. In May 2025, Incyte settled a royalty dispute with Novartis by paying $280.0 million. The $242.2 million gap between the amount accrued and the amount paid was recorded in a line called contract dispute settlement. The company also recorded a $76.3 million impairment on downtown Wilmington properties held for sale.
  • Cash, cash equivalents and marketable securities were $3,580.6 million, versus $2,158.1 million a year earlier. Operating cash flow was $1,413.5 million, versus $335.3 million. Financing activities in 2024 used $2.0 billion, mostly for a share repurchase. The $500.0 million revolving credit facility had no outstanding borrowings.

Risks specific to this company

  • JAKAFI makes up the substantial majority of revenue, and the company expects sales to begin declining when patent exclusivity ends in 2028. It cannot assure that other products will offset the drop.
  • Six generic manufacturers have filed to sell a generic JAKAFI and have challenged its patents (a "paragraph IV" challenge). Incyte settled with Hikma in October 2025 and Granules in February 2026, and the other cases in New Jersey federal court remain pending. Four generic filers are also challenging OPZELURA patents.
  • Incyte sued the U.S. Centers for Medicare and Medicaid Services over whether OPZELURA counts as a "line extension" of JAKAFI for Medicaid rebates. It has accrued approximately $218.5 million for the extra rebates that would be owed if it loses.
  • Drug pricing policy is a named concern, including a May 12, 2025 executive order on "most favored nation" pricing and Inflation Reduction Act changes to Medicare. The company says it qualifies for small-biotech exemptions from price negotiation through 2028.
  • Royalties from Novartis (JAKAVI) and Lilly (OLUMIANT) are a large share of non-product income. Those partners control development and sales in their territories, and can end their agreements for convenience.
  • Incyte relies on outside manufacturers, generally with a single or limited number of qualified suppliers for each material. It also sells mainly through specialty pharmacies and wholesalers. JAKAFI and OPZELURA carry boxed warnings (the FDA's most serious label warning) tied to JAK inhibitor class safety concerns.

What management is watching

  • Management says new products must be developed and commercialized to offset the 2028 loss of JAKAFI exclusivity and the launch of competing products.
  • Research and development spending was $2,050.2 million, with $1,184.7 million going to clinical research and outside services, mainly for late-stage assets. Headcount also grew.
  • Management points to sales allowances (rebates, chargebacks and discounts subtracted from gross sales). A 5% change in them would have moved income before taxes by approximately $103.8 million. Government rebates are expected to rise as a share of gross sales if price increases exceed inflation.
  • On taxes, the One Big Beautiful Bill Act's expensing of domestic research costs will materially reduce U.S. tax liabilities in 2025 and 2026. Because most U.S. deferred tax assets carry no valuation allowance, reported tax expense is expected to be higher in future periods.
  • Management believes operating cash flow, cash and the credit facility are adequate for its capital needs. It keeps open further licensing deals, acquisitions and equity investments.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 29, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Incyte reported a net loss of $784.8 million for the third quarter of 2026, against net income of $424.2 million a year earlier. The swing came from a one-time $1,231.5 million research and development charge for the Vega Therapeutics acquisition. Revenue grew, with total revenues of $1,557.2 million versus $1,366.0 million.

How the business did

  • Revenue: Total revenues were $1,557.2 million for the quarter and $4,503.9 million for the nine months, up from $1,366.0 million and $3,634.4 million. JAKAFI net sales were $826.5 million versus $791.1 million, with the filing citing a 12% rise in paid demand for the quarter. OPZELURA net sales were $254.9 million versus $188.0 million.
  • Fast-growing newer products: ZYNYZ net sales were $58.3 million versus $22.7 million. NIKTIMVO net sales were $67.4 million versus $45.8 million. The filing attributes the growth to strong U.S. uptake and entry into new markets outside the U.S.
  • Unusual items: The Vega charge is for acquired in-process research and development, meaning drug candidates still in testing, which is expensed immediately. It is also non-deductible for tax, so the quarter still carried a tax provision of $96.0 million despite the loss. Separately, in the second quarter the company booked a one-time, non-cash $246.0 million benefit in OPZELURA net sales after settling its Medicaid rebate lawsuit with CMS, the federal Medicare and Medicaid agency.
  • Cash: Cash, cash equivalents and marketable securities were $3.9 billion at September 30, 2026. Operating cash flow for the nine months was $201.7 million versus $870.2 million, which the filing attributes mainly to the cash paid for Vega. The $500.0 million credit facility had no outstanding borrowings.

What management is watching

  • Near-term pipeline events: The filing lists a European Commission decision on povorcitinib for hidradenitis suppurativa (a painful skin condition) in the fourth quarter of 2026. It also lists possible U.S. approvals in the first quarter of 2027 for povorcitinib and for tafasitamab as a first-line treatment for DLBCL, a type of lymphoma. Phase 3 results for povorcitinib in prurigo nodularis (an itchy skin condition) and for ruxolitinib cream in hidradenitis suppurativa are expected in the fourth quarter of 2026.
  • Spending priorities: Clinical research and outside services rose to $317.2 million from $278.9 million, reflecting investment in late-stage assets. Management shifted its ovarian cancer program toward first-line maintenance, discontinuing enrollment in MAESTRA-2 and planning a new Phase 3 study, MAESTRA-3, for the fourth quarter of 2026.
  • JAKAFI exclusivity: The filing says the ruxolitinib patents expire in mid and late 2028. JAKAFI XR, an extended-release version, was approved in May 2026.

New or changed risks

  • Acquisition risk: The risk factors now cite the July 2026 Vega acquisition as an example of deals that can bring integration problems, unknown liabilities and programs that fail to pay off.
  • JAKAFI generics: The filing says JAKAFI sales are expected to begin declining when patent exclusivity ends in 2028. Patent suits against several generic makers remain pending, while settlements were reached with six others.
  • Drug pricing policy: The filing discusses "most favored nation" pricing, which could tie U.S. prices to those in other developed nations. It says the impact is uncertain. It also notes the ORPHAN Cures Act delayed the timeline for ruxolitinib phosphate to become eligible for Medicare price negotiation.
  • Taxes: The company anticipates electing a new global minimum tax safe harbor for 2026. If it does not obtain that treatment, it says it could face higher tax provisions and liabilities.

Follow INCY in Kortex

The Kortex app shows INCY's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.